Searched for
SHASUN PHARMACEUTICALS LTD.
Shasun Pharma gets US FDA nod to market CarisoprodolShasun Pharmaceuticals said the product will be manufactured at its Puducherry plant and distributed through a partner.- Buy Shasun Pharmaceuticals Ltd with a target of Rs 381: Ashwani Gujral'Shasun Pharmaceuticals Ltd is a 'BUY' call with a target of Rs 381 and a stop loss of Rs 362'
- CCI gives green signal to merger of Shasun Pharma with StridesThe combination of Strides and Shasun would create a company with a turnover of Rs 2,500 crore, placing the combined entity among the top 1...
- Shasun gets shareholder nod for merger with Strides ArcolabShareholders of Shasun Pharmaceuticals have approved its merger proposal with drug firm Strides Arcolab.
- Shasun Pharmaceuticals seeks shareholder nod for merger with Strides ArcolabIn a filing to the BSE, Shasun Pharmaceuticals said it is seeking shareholders nod for the merger scheme through a postal ballot.
- Strides Arcolab shares gain 9% on merger with Shasun PharmaShares of Strides Arcolab gained over 9 per cent today after the company and Shasun Pharmaceuticals announced their merger .
- Strides, Shasun announce merger; to create Rs 2,500 crore entityBased on the exchange ratio, Shasun shareholders will own 26 per cent of the combined entity.
- Buy Shasun Pharmaceuticals Ltd with a target of 212: Ashwani Gujral'Shasun Pharmaceuticals Ltd is a 'BUY' call with a target of Rs 212 and a stop loss of Rs 195.'
- Buy Shasun Pharmaceuticals Ltd with a target of Rs 142: Ashwani GujralShasun Pharmaceuticals Ltd is a 'buy' call with a target of Rs 142 and a stop loss of Rs 120.
- Shasun Pharmaceuticals shares surge over 7% on completion of regulatory inspectionShares of Shasun Pharmaceuticals surged in trade today after the company announced that it successfully completed the USFDA inspection.
- Buy Shasun Pharma with a price target of Rs 81: Sandeep WagleShasun Pharmaceuticals Ltd is a 'buy' call with a target of Rs 81 and a stop loss of Rs 69.
- Shasun Pharmaceuticals in licensing pact with Swiss-based DebiopharmShasun Pharmaceuticals would be able to use the Debiopharm technology for manufacturing synthetic Huperzine-A and commercialise it.
- Shasun Pharmaceutical’s UK subsidiary would not be impacted from declining sales of IncevikShasun Pharmaceutical’s stock gained 12.6% today after the company came out with an update on its UK subsidiary.
- Buy Shasun Pharmaceuticals with target of Rs 195: Sandeep WagleBuy Shasun Pharmaceuticals with a target of Rs 195 and a stop loss of Rs 172.
- Buy Shasun Pharmaceuticals with target of Rs 182: Ashwani GujralBuy Shasun Pharmaceuticals with a target of Rs 182 and a stop loss of Rs 174.
- Buy Shasun Pharmaceuticals with a target of 145: Sandeep WagleShasun Pharmaceuticals Ltd is a ‘BUY’ call with a target of Rs 145 and a stop loss of Rs 126.
- Shasun Pharmaceuticals Q4 net up 53% at Rs 59 croreShasun Pharmaceuticals today reported a 53.57% rise in consolidated net profit at Rs 58.99 crore for the fourth quarter ended March 31, 201...
- Shasun Pharmaceuticals to sell 11.93 stake to US firm OrbiMed for Rs 50 croreShasun Pharmaceuticals said its board has approved to sell 11.93 per cent stake to US- based healthcare investment firm OrbiMed for Rs 50 c...
- Shasun Pharmaceuticals aims to be Rs 2,000 cr company by 2015Shasun Pharmaceuticals today said it aims to achieve revenues of Rs 2,000 crore by the end of 2015.
- We see healthy results going forward: S. Vimal Kumar, Shasun PharmaceuticalsS. Vimal Kumar, Managing Director, Shasun Pharmaceuticals Limited in an interview with ET Now talks about the year ahead for the company.
Load More
